推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

ANNALS OF ONCOLOGY

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 ANN ONCOL最新评论:审稿速度:3.0 | 投稿命中率:25.0偏重的研究方向:肿瘤经验分享:为什么现在首页打不开 (2023-07-17)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


ANNALS OF ONCOLOGY期刊基本信息Hello,您是该期刊的第74172位访客


基本信息 登录收藏
期刊名字ANNALS OF ONCOLOGYANNALS OF ONCOLOGY

ANN ONCOL
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
9.7
51人评分
我要评分

声誉
10.0

影响力
9.5

速度
9.7

期刊ISSN0923-7534
微信扫码收藏此期刊
E-ISSN1569-8041
2023-2024最新影响因子
(数据来源于搜索引擎)
56.7 点击查看影响因子趋势图
实时影响因子 截止2024年3月26日:34
2023-2024自引率0.90%点击查看自引率趋势图
五年影响因子38.2
h-index 210
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
63.9013.9428.474
学科分区排名百分位
大类:Medicine
小类:Oncology
Q14 / 404
大类:Medicine
小类:Hematology
Q12 / 137

期刊简介
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.

Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.
期刊官方网站http://annonc.oxfordjournals.org/
期刊投稿网址http://www.oxfordjournals.org/our_journals/annonc/for_authors/submission_online.html
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足ANNALS OF ONCOLOGY的语言要求,还能让ANNALS OF ONCOLOGY编辑和审稿人得到更好的审稿体验,让稿件最大限度地被ANNALS OF ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP
出版商Oxford University Press
涉及的研究方向医学-肿瘤学
出版国家或地区ENGLAND
出版语言English
出版周期Monthly
出版年份1990
年文章数 72点击查看年文章数趋势图
Gold OA文章占比88.05%
研究类文章占比:
文章 ÷(文章 + 综述)
94.44%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:1区

按学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ14/322
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 3区1区3区
ONCOLOGY
肿瘤学
4区1区1区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 2区1区3区
ONCOLOGY
肿瘤学
3区3区1区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 2区1区4区
ONCOLOGY
肿瘤学
2区2区1区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0923-7534%5BISSN%5D
平均审稿速度网友分享经验:
很快,2-3周
平均录用比例网友分享经验:
较难
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在ANNALS OF ONCOLOGY顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 ANNALS OF ONCOLOGY期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 ANNALS OF ONCOLOGY中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
ANNALS OF ONCOLOGY上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    Nature Reviews Clinical Oncology12799.40
    NATURE REVIEWS CANCER396111.90
    CANCER CELL29555.20
    JOURNAL OF CLINICAL ONCOLOGY49441.20
    LANCET ONCOLOGY27462.10
    CANCER RESEARCH41116.10
    SEMINARS IN CANCER BIOLOGY13426.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6718.20
    CLINICAL CANCER RESEARCH29220.10
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE626434
    BIOMATERIALS531739
    BIOMEDICINE & PHARMACOTHERAPY492798
    Journal of Materials Chemistry B473752
    Frontiers in Pharmacology472884
    Frontiers in Immunology446117
    JOURNAL OF ETHNOPHARMACOLOGY425362
    COLLOIDS AND SURFACES B-BIOINTERFACES415859
    COMPUTERS IN BIOLOGY AND MEDICINE405767
    Frontiers in Oncology402462
  •  

    ANNALS OF ONCOLOGY ANNALS OF ONCOLOGY
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial

    Author: Tang, H.; Wang, H.; Fang, Y.; Zhu, J. Y.; Yin, J.; Shen, Y. X.; Zeng, Z. C.; Xiang, D. X.; Hou, Y. Y.; Du, M.; Lian, C. H.; Zhao, Q.; Jiang, H. J.; Gong, L.; Li, Z. G.; Liu, J.; Xie, D. Y.; Li, W. F.; Chen, C.; Zheng, B.; Chen, K. N.; Dai, L.; Liao, Y. D.; Li, K.; Li, H. C.; Zhao, N. Q.; Tan, L. J.
    Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 2, pp. 163-172. DOI: 10.1016/j.annonc.2022.10.508
        PubMed      DOI
    2.Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

    Author: Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Rivera, F.; Alves, G. V.; Garrido, M.; Shiu, K. -k.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F. J. S. M.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, D-y.
    Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 3, pp. 319-320. DOI: 10.1016/j.annonc.2023.01.006
        DOI
    3.Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

    Author: Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. -J.; Takahashi, S.; Weiss, J.; Machiels, J. -P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C. -Y.; Thungappa, S. C.; Segura, P. P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P. -S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R. F.; Yovine, A.; Kurland, J. F.; Morsli, N.; Seiwert, T. Y.
    Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 3, pp. 262-274. DOI: 10.1016/j.annonc.2022.12.008
        PubMed      DOI
    4.Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

    Author: Mok, T. S. K.; Lopes, G.; Cho, B. C.; Kowalski, D. M.; Kasahara, K.; Wu, Y. -l.; de Castro Jr, G.; Turna, H. Z.; Cristescu, R.; Aurora-Garg, D.; Loboda, A.; Lunceford, J.; Kobie, J.; Ayers, M.; Pietanza, M. C.; Piperdi, B.; Herbst, R. S.
    Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 4, pp. 377-388. DOI: 10.1016/j.annonc.2023.01.011
        PubMed      DOI
    5.Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Author: Hendriks, L. E.; Kerr, K. M.; Menis, J.; Mok, T. S.; Nestle, U.; Passaro, A.; Planchard, D.; Peters, S.; Smit, E. F.; Solomon, B. J.; Veronesi, G.; Reck, M.; SMO Guidelines Comm
    Journal: ANNALS OF ONCOLOGY. 2023; Vol. 34, Issue 4, pp. 358-376. DOI: 10.1016/j.annonc.2022.12.013
        PubMed      DOI
    6.Biological background of the genomic variations of cf-DNA in healthy individuals.

    Author: Liu J1,2, Chen X3, Wang J4,5, Zhou S1, Wang CL1, Ye MZ6, Wang XY1, Song Y1, Wang YQ1, Zhang LT1, Wu RH1, Yang HM4,5, Zhu SD4, Zhou MZ6, Zhang XC7, Zhu HM3, Qian ZY3.
    Journal: Ann Oncol. 2019 Mar 1;30(3):464-470. doi: 10.1093/annonc/mdy513.
        PubMed      DOI
    7.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

    Author: Muro K1, Van Cutsem E2, Narita Y1, Pentheroudakis G3, Baba E4, Li J5, Ryu MH6, Zamaniah WIW7, Yong WP8, Yeh KH9,10, Kato K11, Lu Z12, Cho BC13, Nor IM14, Ng M15, Chen LT16, Nakajima TE17, Shitara K18, Kawakami H19, Tsushima T20, Yoshino T18, Lordick F21,22, Martinelli E23, Smyth EC24, Arnold D25, Minami H26, Tabernero J27, Douillard JY28.
    Journal: Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502.
        PubMed      DOI
    8.Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma-a 'Virtual Reality' of the tumor microenvironment?

    Author: Ma BBY1.
    Journal: Ann Oncol. 2019 Jan 1;30(1):8-10. doi: 10.1093/annonc/mdy516.
        PubMed      DOI
    9.Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

    Author: Wu YL1, Planchard D2, Lu S3, Sun H4, Yamamoto N5, Kim DW6, Tan DSW7, Yang JC8, Azrif M9, Mitsudomi T10, Park K11, Soo RA12, Chang JWC13, Alip A14, Peters S15, Douillard JY16.
    Journal: Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554.
        PubMed      DOI
    10.HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.

    Author: Wang Y1, Jiang T1, Qin Z2, Jiang J3, Wang Q3, Yang S1, Rivard C4, Gao G1, Ng TL4, Tu MM5,6, Yu H4, Ji H1,2, Zhou C1, Ren S1,4, Zhang J7, Bunn P4, Doebele RC4, Camidge DR4, Hirsch FR4.
    Journal: Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542.
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386173.60
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Materials61119.40
    Nature Reviews Disease Primers4876.70
 
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共77条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室